Pixium Vision announces the publication of PRIMA results, a wireless subretinal implant, in Nature Medicine

Compelling results show photovoltaic restoration of sight with high visual acuity

Paris, 27 April 2015 – Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces that the preclinical results of PRIMA, its photovoltaic wireless subretinal implant, are published today in Nature Medicine.

The study, led by Professor Daniel Palanker from the Department of Ophthalmology and Hansen Experimental Physics Laboratory at Stanford University, demonstrated PRIMA's ability to restore visual acuity to half of the normal level in rats with retinal degeneration at stimulation thresholds far below the ocular safety limits. Importantly, Optical Coherence Tomography (OCT) demonstrated good preservation of the inner retina one year after implantation.

Professor Daniel Palanker from the Department of Ophthalmology and Hansen Experimental Physics Laboratory at Stanford University and academic partner of Pixium Vision said *"Pre-clinical results of the wireless subretinal photovoltaic arrays we have developed are very encouraging. They demonstrate that network-mediated retinal stimulation preserves many features of natural vision. I'm very happy to see confirmation of the single pixel resolution in-vivo, and I'm looking forward to upcoming clinical trials of these implants."*

Khalid Ishaque, CEO of Pixium Vision said *"We are pleased by the publication of the PRIMA results in the prominent Nature Medicine. Being recognized by such a prestigious scientific journal underscores the potential of PRIMA and the interest of the scientific community in bionic vision as a treatment option for retinal degenerative diseases such as retinitis pigmentosa and macular degeneration."*

Find the publication on:
http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.3851.html

Contacts

Pixium Vision
Pierre Kemula, CFO
investors@pixium-vision.com
+33 1 76 21 47 30
@PixiumVision

Investor Relations
Citigate Dewe Rogerson
Lucie Larguier – Laurence Bault
pixium-vision@citigate.fr
+33 1 53 32 84 78

Presse relations
Newcap Media
Annie-Florence Loyer –
Nadège Le Lezec
afloyer@newcap.fr
nlelezec@newcap.fr

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision's VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. The approval of IRIS® is expected in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

Pixium Vision is listed on Euronext (Compartment C) in Paris.
ISIN: FR0011950641; Mnemo: PIX
IRIS® is a trademark of Pixium-Vision SA

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).